anti-CD19 chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics
Latest Information Update: 07 Jul 2016
At a glance
- Originator Innovative Cellular Therapeutics
- Class Antineoplastics; CAR-T cell therapies
- Mechanism of Action Apoptosis stimulants; Gene expression modulators; Gene transference; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown B cell lymphoma; Leukaemia